Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-20 12:07 |
6-K
|
English | 48.9 KB | ||
| 2024-12-19 18:00 |
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de S…
|
French | 124.2 KB | ||
| 2024-12-19 18:00 |
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
|
English | 116.1 KB | ||
| 2024-12-17 13:30 |
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvaki…
|
French | 246.7 KB | ||
| 2024-12-17 13:30 |
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class po…
|
English | 234.9 KB | ||
| 2024-12-17 07:30 |
Communiqué de presse : Mise en ligne du document « Q4 2024 Aide-mémoire »
|
French | 131.7 KB | ||
| 2024-12-17 07:30 |
Press Release: Availability of the Q4 2024 Aide-mémoire
|
English | 128.6 KB | ||
| 2024-12-13 17:07 |
6-K
|
English | 72.5 KB | ||
| 2024-12-13 07:00 |
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-…
|
English | 178.2 KB | ||
| 2024-12-13 07:00 |
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament i…
|
French | 187.3 KB | ||
| 2024-12-11 07:00 |
Communiqué de presse : Examen accéléré accordé aux États-Unis à deux candidats-…
|
French | 170.5 KB | ||
| 2024-12-11 07:00 |
Press Release: Two combination vaccine candidates for prevention of influenza a…
|
English | 175.4 KB | ||
| 2024-12-09 20:06 |
Communiqué de presse : ASH : les associations thérapeutiques avec Sarclisa proc…
|
French | 268.9 KB | ||
| 2024-12-09 20:06 |
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in …
|
English | 242.1 KB | ||
| 2024-12-07 17:30 |
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in t…
|
English | 206.0 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
